Ketamine | Jotup

Silo Pharma Files Patent for Groundbreaking Ketamine Implant Therapeutic to Target Fibromyalgia and Chronic Pain

Retrieved on:

Monday, March 18, 2024

Combination, Fibromyalgia, Patent, Chronic pain, SILO, Ketamine, Therapy, Administration, Medical device

SARASOTA, FL, March 18, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced that it has filed a provisional patent application titled ‘Methods and Combinations for Managing Pain’ with the United States Patent and Trademark Office (USPTO).

Key Points:

The patent application includes protection for the Company’s SP-26 implantable drug delivery system for a novel time-released, dose-controlled formulation of ketamine, initially targeted for fibromyalgia.
Silo believes that implantable drug delivery may be well-suited for chronic pain management.
“Our SP-26 implant technology is designed to deliver a steady, low dose of ketamine for sustained relief of chronic pain,” said Eric Weisblum, CEO of Silo.
If approved, SP-26 could be the first at-home approved ketamine based therapeutic.”
The next tests of the SP-26 ketamine implant will measure drug dissolution and time-release action.

Melt Pharmaceuticals Closes $24 Million Series B Preferred Stock Financing

Retrieved on:

Tuesday, April 2, 2024

Medical Supplies, Biotechnology, FDA, Health, Pharmaceutical, Optical, Health Technology, Medical Devices, Hospitals, Surgery, Clinical Trials, Catalent, Series, Absorption, Midazolam, Ketamine, Medication

Melt Pharmaceuticals, Inc. (“Melt”), a clinical‑stage pharmaceutical company developing novel approaches for procedural sedation, today announced the completion of its Series B Preferred Stock financing of approximately $24 million from new and existing investors at a pre‑money valuation that increased nearly 150% from the pre-money valuation for Melt’s Series A Preferred Stock financing in 2019.

Key Points:

Melt Pharmaceuticals, Inc. (“Melt”), a clinical‑stage pharmaceutical company developing novel approaches for procedural sedation, today announced the completion of its Series B Preferred Stock financing of approximately $24 million from new and existing investors at a pre‑money valuation that increased nearly 150% from the pre-money valuation for Melt’s Series A Preferred Stock financing in 2019.
The capital raised will primarily support the further development of MELT-300, including the MELT-300 Phase 3 program.
“With this round of financing, we’ve obtained the funding to further the development of MELT-300, including conducting our recently commenced Phase 3 program.
Their shared belief in the vision of MELT-300 and their confidence in its potential to revolutionize short-duration procedural sedation is incredibly valuable to us.”
Newbridge Securities Corporation acted as the exclusive placement agent for the Series B Preferred Stock Offering.

Minneapolis Psychiatry Clinic Adds Vagus Nerve Stimulation as Non-Drug Therapy for Severe Depression

Retrieved on:

Wednesday, March 20, 2024

Advanced Brain + Body Clinic Ketamine TMS (AB+BC), specialists in treatment-resistant depression and other severe mental health conditions, added Vagus Nerve Stimulation (VNS) as an FDA-approved, non-medication treatment option for severe or bipolar depression.

Key Points:

Advanced Brain + Body Clinic Ketamine TMS (AB+BC), specialists in treatment-resistant depression and other severe mental health conditions, added Vagus Nerve Stimulation (VNS) as an FDA-approved, non-medication treatment option for severe or bipolar depression.
VNS has a 70% success rate when used for treatment resistant depression, meaning the patient hasn’t responded to traditional antidepressants.
VNS stimulates the vagus nerve, triggering its natural process of sending electrical pulses to the parts of the brain that control mood.
For more information about Vagus Nerve Stimulation and what to expect, visit Advanced Brain and Body Clinic’s VNS page .

Solace Behavioral Health Selects Core Solutions' Cx360 HER

Retrieved on:

Tuesday, March 12, 2024

Health, Documentation, Growth, Schizophrenia, Clozapine, MIPS, LCSW, Transcranial magnetic stimulation, TMS, Mental health, Consolation, MD, Senior counsel, Ketamine, EHR, Core

KING OF PRUSSIA, Pa., March 12, 2024 /PRNewswire/ -- Core Solutions, Inc., (Core) is pleased to announce that Solace Behavioral Health has selected its Cx360 behavioral health electronic health record (EHR) solution. This selection reflects the organization's ongoing commitment to incorporating cutting-edge solutions that strengthen access to mental health and substance use care and deliver positive outcomes.

Key Points:

KING OF PRUSSIA, Pa., March 12, 2024 /PRNewswire/ -- Core Solutions, Inc., (Core) is pleased to announce that Solace Behavioral Health has selected its Cx360 behavioral health electronic health record (EHR) solution.
Solace is one of the largest behavioral health providers in Florida, offering a wide range of therapies and techniques at its four locations.
In addition to traditional behavioral health services, such as psychiatric evaluation, counseling, addiction treatment, intensive outpatient, and detox, Solace offers solutions that help distinguish the organization from other providers.
Core Solutions and its Cx360 EHR will further enable our team to leverage targeted interventions that empower clients on their journey to improved health."

Beckley Waves Celebrates a Year of Milestones, Including $3.3 Million in New Funding, 200 Retreat Participants, the Inaugural Cohort of Therapist Training, and the Acquisition of Ketamine Therapy Provider Nue Life

Retrieved on:

Tuesday, March 5, 2024

Psilocybin, Mental health, Woman, ICL, Research, Beckley Foundation, Suicide, Spirituality, Curriculum, Entrepreneurship, MDMA, BIPOC, Ketamine, Veteran, PAT, Imperial College London, Partnership

Through its portfolio of operating companies, Beckley Waves has also expanded programs for practitioner training and psilocybin retreats, accelerating the company’s growth.

Key Points:

Through its portfolio of operating companies, Beckley Waves has also expanded programs for practitioner training and psilocybin retreats, accelerating the company’s growth.
In September, the company also acquired at-home ketamine therapy provider Nue Life and will continue Nue Life’s work to provide safe and scalable access to ketamine-assisted therapy in underserved areas across multiple US states.
In 2024, Beckley Retreats will offer dedicated retreats in Jamaica and the Netherlands that will be exclusively for women, veterans, and the BIPOC community.
"With our ongoing momentum, we will keep the flywheel spinning and continue to allow the Beckley Waves Ecosystem to play a catalytic role in our shared path to widespread access."

SciSparc-Clearmind Partnership Yields Three New International Patent Applications for MDMA, Ibogaine and Ketamine Compounds

Retrieved on:

Tuesday, February 27, 2024

Therapy, Central nervous system, TEL, Obesity, Ketamine, Patent, Ibogaine, PCT, Patent Cooperation Treaty, MDMA, PEA, CWY, Disorder, DSM-IV codes, Pharmaceutical industry

The patent applications refer to novel proprietary compositions of 3,4-methylenedioxymethamphetamine (MDMA), ibogaine, and ketamine, each combined with palmitoylethanolamide (“PEA”), the active ingredient of SciSparc's proprietary CannAmide™.

Key Points:

The patent applications refer to novel proprietary compositions of 3,4-methylenedioxymethamphetamine (MDMA), ibogaine, and ketamine, each combined with palmitoylethanolamide (“PEA”), the active ingredient of SciSparc's proprietary CannAmide™.
These applications were previously filed as provisional patent applications with the United States Patent and Trademark Office (“USPTO”).
As part of this collaboration, eight other applications have been filed by Clearmind with the USPTO for various combinations, three of which are for the combination of PEA with Clearmind’s 5-methoxy-2-aminoindane compound for the treatments of alcohol use disorder, cocaine addiction and obesity and its related metabolic disorders.
In addition, seven applications were filed under the PCT.

Beckley Academy Publishes First Open-Source Learning Framework to Advance Psychedelic-Assisted Therapy Training Standards

Retrieved on:

Tuesday, February 27, 2024

Psilocybin, MAPS, APPA, Risk, MDMA, Business, Organization, Ketamine, PAT, Publication, Research, Nursing

NEW YORK, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Beckley Academy , the learning studio that prepares and trains practitioners to provide psychedelic-assisted therapy (PAT) with Ketamine, Psilocybin, and MDMA, announced today the open-source publication of its research: A Psychedelic-Assisted Therapy Learning Framework .

Key Points:

NEW YORK, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Beckley Academy , the learning studio that prepares and trains practitioners to provide psychedelic-assisted therapy (PAT) with Ketamine, Psilocybin, and MDMA, announced today the open-source publication of its research: A Psychedelic-Assisted Therapy Learning Framework .
This industry-first learning framework will serve as a much-needed foundation to advance national training standards for clinicians to provide ethical and effective psychedelic-assisted therapy.
Currently, no national training standards or certifications exist for psychedelic practitioners, though many organizations have independently created training programs, practice guidelines, and codes of ethics.
Beckley Academy co-founding team members Deborah Gardner and Shirelle Noble recognized the opportunity to analyze existing publications and create a unified framework.

Six Years Strong: Founder of Revitalist Kathryn Walker’s Continuous Leadership in Revolutionizing Mental Health Care

Retrieved on:

Friday, February 23, 2024

The COVID-19 pandemic especially, has exacerbated mental health issues, with increased mood disorders, substance use, and suicidal ideation rates.

Key Points:

The COVID-19 pandemic especially, has exacerbated mental health issues, with increased mood disorders, substance use, and suicidal ideation rates.
Kate NeuroPsych represents a groundbreaking approach to mental health care — offering 24/7 availability, personalized recommendations, and worldwide access — being designed by scientific leaders who are positively disrupting healthcare delivery at Revitalist and Sama Therapeutics .
Looking ahead, Kathryn envisions a future where psychedelics are normalized as essential tools in mental health care.
With each milestone she achieves, Kathryn Walker continues to redefine the boundaries of mental health care and inspire hope for a brighter, more compassionate future.

Gabather reports initial positive results from the EEG/fMRI target engagement study

Retrieved on:

Thursday, March 7, 2024

Anxiety, SAD, GABAA, Benzodiazepine, Ketamine, Deficit spending, Schizophrenia, BZD, Dog, Rat, PAM, Learning, Relaxation, Safety, Phencyclidine, Attention, Alpha, Memory, EEG, Patient, DSM-IV codes, Social, Lorazepam, Mouse, Brain, Medical imaging

STOCKHOLM, March 7, 2024 /PRNewswire/ -- Gabather AB (Nasdaq First North Growth Market: GABA) today reports initial positive results from the EEG/fMRI target engagement study, a double-blinded placebo-controlled, cross-over phase Ib study of Gabather's GABAA-receptor positive allosteric modulator, GT-002, in healthy volunteers.

Key Points:

STOCKHOLM, March 7, 2024 /PRNewswire/ -- Gabather AB (Nasdaq First North Growth Market: GABA) today reports initial positive results from the EEG/fMRI target engagement study, a double-blinded placebo-controlled, cross-over phase Ib study of Gabather's GABAA-receptor positive allosteric modulator, GT-002, in healthy volunteers.
The study met the primary objective to confirm a favourable safety and tolerability profile of GT-002.
The secondary objective to demonstrate target engagement in human brain was also met.
The study clearly demonstrated that GT-002 is safe and well tolerated at dose levels expected to be effective for treatment of patients with neuropsychiatric disorders.

Gabather reports initial positive results from the EEG/fMRI target engagement study

Retrieved on:

Thursday, March 7, 2024

STOCKHOLM, March 7, 2024 /PRNewswire/ -- Gabather AB (Nasdaq First North Growth Market: GABA) today reports initial positive results from the EEG/fMRI target engagement study, a double-blinded placebo-controlled, cross-over phase Ib study of Gabather's GABAA-receptor positive allosteric modulator, GT-002, in healthy volunteers.

Key Points:

STOCKHOLM, March 7, 2024 /PRNewswire/ -- Gabather AB (Nasdaq First North Growth Market: GABA) today reports initial positive results from the EEG/fMRI target engagement study, a double-blinded placebo-controlled, cross-over phase Ib study of Gabather's GABAA-receptor positive allosteric modulator, GT-002, in healthy volunteers.
The study met the primary objective to confirm a favourable safety and tolerability profile of GT-002.
The secondary objective to demonstrate target engagement in human brain was also met.
The study clearly demonstrated that GT-002 is safe and well tolerated at dose levels expected to be effective for treatment of patients with neuropsychiatric disorders.